Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Sanofi diabetes products

Toujeo (insulin glargine injection) 300 UnitsmL

9.24.2017 | Logan Miers

Patients were required to stop taking sulfonylureas (a kind of oral diabetes And you'll pay $10 per prescription with the Sanofi Rx Savings Card*, which is.


Toujeo may have additional side effects including swelling, weight gain, low potassium, and injection site reactions which may include change in fat tissue, skin thickening, redness, swelling, and itching.

Toujeo should be taken at the same time once a day. Verify that you have the correct insulin before each injection. Test your blood sugar levels daily while using insulin, including Toujeo. Your dose for Toujeo may be different from other insulins you have taken.

Sanofi Seeking FDA Approval for New Combination

7.22.2017 | Jessica MacAdam

Other well-known GLP-1 agonist drugs for diabetes include Byetta and Bydureon. A GLP-1 drug is a peptide that naturally occurs in the human body, released.

Lixisenatide has already been in approved in Europe three years ago, in 2013, for the “treatment of adults with type 2 diabetes mellitus to achieve glycemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycemic control.”

Lyxumia is the brand name for Lixisenatide in Europe and other countries where the drug is already in use by patients with type 2 diabetes.

What I want to know is how you can possibly mix these drugs? I have T2 and I need to “adjust” my basal.

Novo, Sanofi go head to head as FDA clears new diabetes drugs

3.18.2017 | Jessica MacAdam

Xultophy, approved in Europe since 2014, combines Novo's insulin drug Tresiba with its GLP-1 agonist Victoza. Soliqua is a mix of Sanofi's Lantus and the GLP-1 Lyxumia.

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on, video, mobile, and interactive evision platforms. Learn more about Thomson Reuters products:. Reuters is the news and media division of Thomson Reuters.

Industry analysts expect Xultophy to generate annual sales of around $1.20 billion in 2021, while Soliqua is forecast to reach $550 million by then, according to consensus estimates compiled by Thomson Reuters.

Officials at the Danish and French companies said on Tuesday the rival treatments would be sold at discounts to the combined price of the component ingredients.

LONDON, July 7 At least three people worldwide are infected with totally untreatable "superbug" strains of gonorrhoea which they are likely to be spreading to others through sex, the World Health Organization (WHO) said on Friday.

That is something we will develop over time," Riis told Reuters.


11.26.2017 | Logan Miers

Sanofi is a multinational pharmaceutical company whose headquarters are currently With a expanse range of products that have been developed, they have.

Download the free 440 page, 365 recipe cookbook!

The step-by-step plan to take control of type 2 diabetes, written by Dr David Cavan.

With a expanse range of products that have been developed, they have been successful in creating ones for diabetes to. These are a couple they have manufactured:.

What hypoglycemia is and how to recognise hypoglycemia symptoms.

Sanofi is a multinational pharmaceutical company whose headquarters are currently based in Paris, France.

Take part in diabetes clinical trials.

The company itself is comprised of over 18,000 research staff working in over 21 research and development centres, across three continents.

Discuss complications in the Diabetes Forum.

Join 240,464 people in the Diabetes Forum.

Diet and exercise can help to reverse prediabetes.

What BMI is and how it determines your health outcome.

Talk to other pumpers (people who use a pump).

Ask questions and find support from other people with prediabetes.

Their UK headquarters are at Guildford in Surrey along with a Clinical Research Unit for clinical trials across the UK and Ireland.

Self monitoring can reduce HbA1c in people with type 2.

They have also signed contracts with universities to explore further developments of medicines and therapies.

Sanofi currently deals with seven major areas:

90 recipes for a low carb month.

Download a free chart of the IDF recommended blood glucose ranges.

Get all of the recipes ever published on your phone or tablet.

Ask questions and find support from other people with type 2 diabetes.

Watch our video guide on how to inject insulin.

Knowing how diabetes affects your body can help you look after your body.

Join the Forum ».

Insulins & Insulin Devices Diabetes Matters from Sanofi

8.23.2017 | Noah Becker

Toujeo and Lantus are not bioequivalent and therefore not interchangeable. View the Toujeo prescribing information here; View the Toujeo summary of product.

Toujeo is the brand name for insulin glargine 300 units/mL, an insulin analogue, licensed for adults with type 1 or type 2 diabetes mellitus. Toujeo is a novel formulation of insulin glargine, administered once daily via the Toujeo SoloSTAR, an easy-to-use pen device.

And to provide them with more information on their treatment, we have a range of booklets specifically for patients who have been prescribed one of the following insulins. That's why we've developed a range of insulins and pen devices designed to help your patients understand their treatment and how to store and inject their insulin.